Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Late-breaking data for Abbott's TactiFlex™ Duo Ablation Catheter reveal positive outcomes ...

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at abbott.mediaroom.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Abbott's TactiFlex Duo Ablation Catheter, combining pulsed field ablation and radiofrequency energy, demonstrated high safety and effectiveness in treating complex atrial fibrillation cases as presented at the European Society of Cardiology Congress 2026 with supportive 12-month clinical data.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You have a clearer path to market in the U.S. as Abbott's catheter nears FDA approval with strong clinical backing. Accelerate engagement with electrophysiology specialists now while confidence in ablation therapy rises.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Medtechcardiologymedical-deviceclinical-trialablationatrial-fibrillation